Literature DB >> 31096805

Stability test of novel combined formulated dry powder inhalation system containing antibiotic: physical characterization and in vitro-in silico lung deposition results.

Edit Benke1, Árpád Farkas2, Imre Balásházy2, Piroska Szabó-Révész1, Rita Ambrus1.   

Abstract

Objective: The aim was to study the stability of dry powder inhaler (DPI) formulations containing antibiotic with different preparation ways - carrier-based, carrier-free, and novel combined formulation - and thereby to compare their physicochemical and in vitro-in silico aerodynamical properties before and after storage. Presenting a novel combined technology in the field of DPI formulation including the carrier-based and carrier-free methods, it is the most important reason to introduce this stable formulation for the further development of DPIs.
Methods: The structure, the residual solvent content, the interparticle interactions, the particle size distribution and the morphology of the samples were studied. The aerodynamic values were determined based on the cascade impactor in vitro lung model. We tested the in silico behavior of the novel combined formulated samples before and during storage.
Results: The physical measurements showed that the novel combined formulated sample was the most favorable. It was found that thanks to the formulation technique and the use of magnesium stearate (MgSt) has a beneficial effect on the stability compared with the carrier-based formulation without MgSt and carrier-free formulations. The results of in vitro and in silico lung models were consistent with the physical results, so the highest deposition was found for the novel combined formulated sample during the storage. Conclusions: It can be established that after the storage a novel combined formulated DPI contained amorphous drug to have around 2.5 μm mass median aerodynamic diameter and nearly 50% fine particle fraction predicted high lung deposition in silico also.

Entities:  

Keywords:  assessment; Novel combined formulation; ciprofloxacin hydrochloride; interparticle interactions; magnesium stearate; pulmonary drug delivery; sodium stearate

Mesh:

Substances:

Year:  2019        PMID: 31096805     DOI: 10.1080/03639045.2019.1620268

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  4 in total

1.  Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment.

Authors:  Alanood S Almurshedi; Basmah N Aldosari; Hessah A Aljunaidel; Bushra Alquadeib; Iman M Alfagih; Salma S Almarshidy; Eram K D Eltahir; Amany Z Mohamoud
Journal:  Int J Nanomedicine       Date:  2021-03-25

2.  Stability and In Vitro Aerodynamic Studies of Inhalation Powders Containing Ciprofloxacin Hydrochloride Applying Different DPI Capsule Types.

Authors:  Edit Benke; Patrícia Varga; Piroska Szabó-Révész; Rita Ambrus
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

3.  Development of an Innovative, Carrier-Based Dry Powder Inhalation Formulation Containing Spray-Dried Meloxicam Potassium to Improve the In Vitro and In Silico Aerodynamic Properties.

Authors:  Edit Benke; Árpád Farkas; Piroska Szabó-Révész; Rita Ambrus
Journal:  Pharmaceutics       Date:  2020-06-10       Impact factor: 6.321

4.  Evaluation of the Mucoadhesive Properties of Chitosan-Based Microstructured Lipid Carrier (CH-MLC).

Authors:  Marta Guerini; Giorgia Condrò; Paola Perugini
Journal:  Pharmaceutics       Date:  2022-01-12       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.